Medlive Technology Co., Ltd. provided earnings guidance for the six months ended 30 June 2023. For the period, the company expects to record a significant increase in profit attributable to owners of the parent for 1H2023 to not less than RMB90 million as compared to the profit attributable to owners of the parent of approximately RMB26.97 million for the six months ended 30 June 2022. The Board believes that the increase in revenue from the Group's core business, namely precision marketing and corporate solutions, is mainly due to the medical care at hospital
end has returned to normal and the approval process for new drugs has accelerated after the pandemic, as well as the accelerated recovery of product sales and marketing work of pharmaceutical and medical device company customers. The precision marketing and corporate solutions provided by the Group meet market demand, helping customers to reach physicians throughout the full life cycle of pharmaceutical products and conduct medical academic education in a compliant, precise and efficient manner. This has been widely recognized by pharmaceutical and medical device company customers. As such, the number of healthcare customers of, and the number of products marketed under, the precision marketing and corporate solutions continued to increase in the first half of 2023.